An assay using skin biopsies, called the Syn-One Test, was able to detect the alpha-synuclein protein that characterizes Parkinson’s disease and like conditions in more than 90% of the patients enrolled in a clinical trial. “These results validate cutaneous [skin-based] alpha-synuclein as a reliable biomarker for Parkinson’s disease and…
Parkinson’s News Today is providing virtual coverage of the 2023 Annual Meeting for the American Academy of Neurology taking place April 22-27 in Boston. Stay tuned to this page for all the latest news.
Abbvie is funding a clinical trial called PROSPECT to assess how clinical outcomes and disease burden change over time for people with Parkinson’s disease whose symptoms are not adequately controlled with available treatments. Interim data from the trial, presented at this year’s American Academy of Neurology (AAN) annual…
People with Parkinson’s disease given deep brain stimulation (DBS) targeting the right side of the brain experienced fewer cognitive side effects following treatment compared with those who received the procedure to the left side of the brain, according to new findings from a…
People prescribed certain medications to treat asthma or high blood pressure are less likely to develop Parkinson’s disease, according to an analysis of healthcare data in Norway. The finding implies these therapies may have protective effects in Parkinson’s, which are currently being explored in preclinical models. Trond Riise, PhD,…
IPX203, Amneal Pharmaceuticals‘ investigational extended-release carbidopa/levodopa (CD/LD) treatment for Parkinson’s disease, continued to exhibit a favorable safety and efficacy profile during the open-label extension part of the Phase 3 RISE-PD trial. “IPX203 remained as efficacious and safe as it was shown during the RISE-PD study, and the vast…
Parkinson’s disease patients treated with prasinezumab for three years — as part of a long-term extension of the Phase 2 PASADENA clinical trial — were shown to be at a lower risk of motor symptom progression and motor complications than patients who started treatment a year later, according to…
DopaFuse, a continuous oral levodopa-carbidopa delivery system, led to more stable levels of medication in the blood and better control of symptoms for people with Parkinson’s disease in a small Phase 2 study. Warren Olanow, MD, a neurologist at Mount Sinai, presented findings from the trial at the…
Most people with Parkinson’s disease treated with SPN-830, an apomorphine infusion pump, report improvement in their health status. SPN-830 also reduced “off” time, when symptoms are not being adequately controlled, by an average of about three hours a day. That’s according to new results from an open-label…
Recent Posts
- How being a skilled queen bee prepared me for Parkinson’s caregiving
- Grants fund tests of portable devices in Parkinson’s speech therapy
- Light therapy device seen to brighten life quality for those with Parkinson’s
- When early memories of Parkinson’s came full circle
- FDA grants advanced therapy status to Parkinson’s cell treatment